LIFITEGRAST SOLN,OPH
Clinical Criteria Summary
Exclusion Criteria
- Active ophthalmic infections, including herpes keratitis
- Hypersensitivity to lifitegrast or any of its ingredients
Inclusion Criteria
- Diagnosis of dry eye disease with lack of therapeutic response to at least two artificial tear agents from different categories and a trial of 0.05% cyclosporine eye drops
- Documented corneal surface damage despite frequent use of artificial tears and 0.05% cyclosporine eye drops
Provider Requirements
- Provider must be a VA/VA Community Care ophthalmologist or optometrist
Clinical Considerations & Trial Data
- Artificial tear categories include: Cellulose Derivatives, Liquid Polyols, Polyvinyl Alcohol, Oil containing, and High Viscosity (gel drops, gels, ointments)
- Cyclosporine typically requires 3 to 6 months for increased tear production or improved symptoms; lifitegrast symptom relief may begin as early as 2 weeks with general improvements at 6 and 12 weeks
- Co-administration with punctual occlusion should be reviewed on a patient-by-patient basis due to lack of subgroup efficacy and safety analysis
- Limited data exist for safety and efficacy in ocular graft vs. host disease and corneal transplant rejection